{"id":26465,"date":"2022-08-25T17:53:00","date_gmt":"2022-08-25T09:53:00","guid":{"rendered":"https:\/\/flcube.com\/?p=26465"},"modified":"2025-02-12T18:00:42","modified_gmt":"2025-02-12T10:00:42","slug":"etherna-raises-eur-39m-in-series-b2-to-expand-mrna-services-and-leadership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=26465","title":{"rendered":"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership"},"content":{"rendered":"\n<p>Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million (USD 38.9 million). The round was led by Moderna co-founder Kenneth Chien and Novalis Life Sciences LLC, with participation from existing investors including LSP (EQT Life Sciences), PMV, China&#8217;s Grand Pharma, Fund+, and Omega Fund. The company also announced that CEO Steven Powell will step down, with COO Bernard Sagaert taking over.<\/p>\n\n\n\n<p><strong>Funding and Leadership<\/strong><br>The funds will support eTheRNA&#8217;s transition to a service provider model, leveraging its mRNA engineering, production, and lipid nanoparticle (LNP) capabilities. This shift aims to generate revenue through contract research, mRNA manufacturing, and tech licensing. The company previously provided mRNA-related services, including a February partnership with Germany&#8217;s Merck KGaA.<\/p>\n\n\n\n<p><strong>Strategic Outlook<\/strong><br>Under Bernard Sagaert&#8217;s leadership, eTheRNA plans to expand collaborations with pharma partners, enhancing its mRNA platform to drive new business opportunities. The Series B2 round positions the firm to capitalize on growing demand for mRNA technologies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,3631,20,63],"class_list":["post-26465","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-etherna","tag-finance","tag-mrna"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million (USD 38.9 million). The round was led by Moderna co-founder Kenneth Chien and Novalis Life Sciences LLC, with participation from existing investors including LSP (EQT Life Sciences), PMV, China&#039;s Grand Pharma, Fund+, and Omega Fund. The company also announced that CEO Steven Powell will step down, with COO Bernard Sagaert taking over.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=26465\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=26465\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T09:53:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T10:00:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26465#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26465\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership\",\"datePublished\":\"2022-08-25T09:53:00+00:00\",\"dateModified\":\"2025-02-12T10:00:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26465\"},\"wordCount\":176,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"eTheRNA\",\"Finance\",\"mRNA\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26465#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26465\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=26465\",\"name\":\"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-08-25T09:53:00+00:00\",\"dateModified\":\"2025-02-12T10:00:42+00:00\",\"description\":\"Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million (USD 38.9 million). The round was led by Moderna co-founder Kenneth Chien and Novalis Life Sciences LLC, with participation from existing investors including LSP (EQT Life Sciences), PMV, China's Grand Pharma, Fund+, and Omega Fund. The company also announced that CEO Steven Powell will step down, with COO Bernard Sagaert taking over.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26465#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=26465\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=26465#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership - Insight, China&#039;s Pharmaceutical Industry","description":"Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million (USD 38.9 million). The round was led by Moderna co-founder Kenneth Chien and Novalis Life Sciences LLC, with participation from existing investors including LSP (EQT Life Sciences), PMV, China's Grand Pharma, Fund+, and Omega Fund. The company also announced that CEO Steven Powell will step down, with COO Bernard Sagaert taking over.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=26465","og_locale":"en_US","og_type":"article","og_title":"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=26465","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-08-25T09:53:00+00:00","article_modified_time":"2025-02-12T10:00:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=26465#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=26465"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership","datePublished":"2022-08-25T09:53:00+00:00","dateModified":"2025-02-12T10:00:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=26465"},"wordCount":176,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","eTheRNA","Finance","mRNA"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=26465#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=26465","url":"https:\/\/flcube.com\/?p=26465","name":"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-08-25T09:53:00+00:00","dateModified":"2025-02-12T10:00:42+00:00","description":"Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million (USD 38.9 million). The round was led by Moderna co-founder Kenneth Chien and Novalis Life Sciences LLC, with participation from existing investors including LSP (EQT Life Sciences), PMV, China's Grand Pharma, Fund+, and Omega Fund. The company also announced that CEO Steven Powell will step down, with COO Bernard Sagaert taking over.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=26465#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=26465"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=26465#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26465"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26465\/revisions"}],"predecessor-version":[{"id":26467,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/26465\/revisions\/26467"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}